Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in the Nordic Countries, Denmark, Finland, Iceland, Norway and Sweden, or involving organisations from these countries.

Total search results: 1037 | Ordered by Date (descending)
next pagenext page 1 2 3 4 5 6 7 8 9 10 11  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
BC Platforms–SEVERAL: investment, 201912 financing round Series C $15m led by Iqvia + incl Debiopharm Innovation Fund + Tesi 2019-12-18
Genomill Health–Avohoidon Tutkimussäätiö: investment, 201912 financing round incl co-investor Avohoidon Tutkimussäätiö 2019-12-18
Genomill Health–SEVERAL: investment, 201912 financing round led by Voima Ventures with Avohoidon Tutkimussäätiö 2019-12-18
Genomill Health–Voima Ventures: investment, 201912 financing round incl lead investor Voima Ventures 2019-12-18
BC Platforms–Scius Communications: public relations, 201912 supply service existent by Scius Communications 2019-12-06
Life & Brain–BC Platforms: genomic software tools, 201912– collab using BC Platforms solutions for genotyping services 2019-12-06
Elypta–Chalmers Univ: investment, 201912 late seed financing round totalling €6.1m incl existing + co-investor Chalmers Ventures 2019-12-01
Elypta–Nina Capital: investment, 201912 late seed financing round totalling €6.1m incl co-investor Nina Capital 2019-12-01
Elypta–Norrsken Foundation: investment, 201912 late seed financing round totalling €6.1m incl co-investor Norrsken VC 2019-12-01
Elypta–Sciety: investment, 201912 late seed financing round totalling €6.1m incl co-lead investor Sciety 2019-12-01
Elypta–SEVERAL: investment, 201912 late seed financing round €6.1m co-led by Industrifonden + Sciety 2019-12-01
Elypta–Sweden (govt): investment, 201912 late seed financing round totalling €6.1m incl co-lead investor Industrifonden 2019-12-01
ECBF–SEVERAL: investment, 201911– European Circular Bioeconomy Fund aims to raise €250m incl up to €100m from EIB 2019-11-29
Novo Group–Optimum Strategic Communications: public relations, 201911 service existent by Optimum 2019-11-26
Ferring–Blackstone: investment, 201911– investment $400m by Blackstone Life Sciences in FerGene to develop + market nadofaragene firadenovec 2019-11-25
Veloxis Pharmaceuticals–Asahi Kasei: investment, 201911– recommended cash offer DKK 8.9b ($1.3b) by Asahi Kasei Pharma Denmark A/S 2019-11-25
Zelluna–Glycostem Therapeutics: cell therapy contract manufacturing, 201911– collab developm + supply of TCR-guided NK-cell therapies 2019-11-19
Dicerna Pharmaceuticals–Novo Group: investment, 201911 investment $50m by Novo in connection with r+d collab 2019-11-18
Novo Group–Dicerna Pharmaceuticals: RNAi therapeutics, 201911– collab r+d $175m upfront + milestones + investm RNAi drugs liver diseases using GalXC 2019-11-18
Gyros–Mesa Labs: investment, 201910 acquisition $180m in cash of Gyros Protein Technologies Holding AB by Mesa Laboratories Inc 2019-10-31
Disc Medicine–AbbVie: therapeutics antibodies, 201910– license €na ww excl to series of hemojuvelin antagonist MAbs from AbbVie 2019-10-29
Disc Medicine–Novo Group: investment, 201910 financing round Series A totalling $50m incl new + lead investor Novo Holdings A/S 2019-10-29
Disc Medicine–SEVERAL: investment, 201910 financing round Series A $50m led by Novo Holdings A/S 2019-10-29
OpGen–SEVERAL: investment, 201910 underwritten public offering $9.4m 2019-10-23
Encycle Therapeutics–Zealand Pharma: investment, 201910 acquisition of Encycle Therapeutics for up to $80m 2019-10-22
Bavarian Nordic–GSK: vaccines, 201910 acquisition up to €796m incl €301m upfront of manufacturing + global rights to Rabipur/RabAvert + Encepur by BN 2019-10-21
Sofinnova–SEVERAL: investment, 201910 closing €333m of Sofinnova Capital IX fund 2019-10-17
Amarna Therapeutics–Flerie Invest: investment, 201910 financing round totalling €10m incl lead investor Flerie Invest AB + incl RVO innovation credit 2019-10-16
Amarna Therapeutics–Netherlands (govt): credit, 201910 financing round totalling €10m incl substantial innovation credit from RVO.nl 2019-10-16
Amarna Therapeutics–PERSON: investment, 201910 financing round totalling €10m incl existing + co-investor Pim Berger + incl RVO innovation credit 2019-10-16
Amarna Therapeutics–SEVERAL: investment, 201910 financing round €10m led by Flerie Invest AB + incl innovation credit from RVO.nl 2019-10-16
Novo Group–Bluebird Bio: gene therapy, 201910–202209 collab r+d 3y utilising megaTAL technology to develop hemophilia A gene therapies 2019-10-09
Vivoryon–SEVERAL: investment, 201910– public rights offering €30m–€70m incl Claus Chrisitansen + Den Danske Forskningsfond + T&W Holding + MorphoSys 2019-10-08
Lundbeck–LeadXPro: drug discovery services, 201910– collab structural proteomics services using X-ray + cryo-EM for small molecule drug discovery 2019-10-07
Technical Univ Denmark–Inscripta: genome engineering technology, 201910 supply existent TUD NNFCB early customer Onyx Genome Engineering platform 2019-10-01
STipe Therapeutics–SEVERAL: investment, 201909 financing round Series A €20m co-led by Arix Bioscience + Novo Holdings 2019-09-30
Themis Bioscience–Hadean Ventures: investment, 201909 financing round Series D totalling €40m incl new + co-lead investor Hadean Ventures 2019-09-18
Themis Bioscience–SEVERAL: investment, 201909 financing round Series D €40m co-led by Farallon Capital + Hadean Ventures 2019-09-18
Alder Biopharmaceuticals–Lundbeck: investment, 201909–201910 acquisition tender offer in cash + CVRs up to $1.95b net of cash 2019-09-16
Orion Corp–Genedata: bioinformatics, 201909– supply license to Genedata Biologics as SaaS for large-molecule r+d to Orion Pharma 2019-09-11
Genmab–Tempus Labs: AI-based drug discovery, 201909– strateg collab multi-year r+d targets + biomarker for personalised cancer drugs 2019-09-09
Sigrid Therapeutics–Axilium Capital: investment, 201909 financing round totalling $1.6m incl co-investor Axilium Capital 2019-09-05
Sigrid Therapeutics–Joyance Partners: investment, 201909 financing round totalling $1.6m incl co-lead investor Joyance Partners 2019-09-05
Sigrid Therapeutics–PERSON: investment, 201909 financing round totalling $1.6m incl co-investor Karsten Inde 2019-09-05
Sigrid Therapeutics–PERSON: investment, 201909 financing round totalling $1.6m incl co-lead investor Pär Gellerfors 2019-09-05
Sigrid Therapeutics–SEVERAL: investment, 201909 financing round $1.6m led by Joyance Partners + Pär Gellerfors 2019-09-05
Curetis–OpGen: investment, 201909– reverse merger with Curetis shareholders holding 72.5% of combined entity 2019-09-04
Protelux (RU)–Unibio: protein production from methane, 201908 collab existing buidling + operating plant for Uniprotein production in Russia 2019-08-28
Unibio–SEVERAL: investment, 201908 financing round $15m (£12.4m) from existing + new shareholders led by West Hill Capital 2019-08-28
Unibio–West Hill Capital: investment, 201908 financing round totalling $15m (£12.4m) incl lead investor West Hill Capital 2019-08-28
Nanovi–SEVERAL: investment, 201908 financing round DKK19m from existing investors 2019-08-27
Biotheus–Alligator Bioscience: therapeutic antibodies, 201908– license to Ab from Alligator-Gold library for bispecific molecules for Greater China 2019-08-20
Cytena–Cellink: investment, 201908 acquisition €30.25m of Cytena GmbH by Cellink AB 2019-08-05
Babylon Health–SEVERAL: investment, 201908 financing round $550m from existing + new investors 2019-08-02
Alizé Pharma–Kurma: investment, 201907 financing round Series A €67m incl Kurma Partners 2019-07-31
Alizé Pharma–SEVERAL: investment, 201907 financing round Series A €67m of Alizé Pharma 3 led by LSP 2019-07-31
OncoImmunity–NEC: investment, 201907 acquisition by NEC and renamed NEC OncoImmunity AS 2019-07-29
Genmab–SEVERAL: investment, 201907 US IPO $581.6m with 28.5m+4.275m ADSs at $17.75/ADS with 10 ADSs/share at Nasdaq Global Select Market 2019-07-22
Medicxi Ventures–JnJ: investment, 201907 closing totalling €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC 2019-07-19
Medicxi Ventures–Novartis: investment, 201907 closing totalling €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC 2019-07-19
Medicxi Ventures–SEVERAL: investment, 201907 closing €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC 2019-07-19
Genmab–Blink Biomedical: therapeutic antibodies, 201907– license to use CD47 Abs in DuoBodies $2.25m upfront + up to $200m per product plus royalties 2019-07-12
Nanoform–Notch Communications: public relations, 201907 service existent by Notch 2019-07-10
IGM Biosciences–Haldor Topsøe: investment, 201907 financing round Series C totalling $102m incl existing + founding investor Haldor Topsøe Holding A/S 2019-07-08
IGM Biosciences–SEVERAL: investment, 201907 financing round Series C $102m incl Redmile Group + Janus Henderson + Vivo Capital et al 2019-07-08
Danaher–Cobo Technologies: protein expression analysis, 201907– collab co-marketing PIPPR platform with SWATH Acquisition + Sciex TripleTOF 6600 2019-07-05
Nanoform–SEVERAL: investment, 201907 private placement €10m incl Ilmarinen Mutual Pension Insurance + Mandatum Life Insurance 2019-07-03
ExpreS2ion Biotech–ERS Genomics: CRISPR technology, 201907– license non-excl €na for use + commercialisation of products from ERS Genomics 2019-07-01
Yahong Meditech–Photocure: Cevira®, 201907– license ww developm + commercialisation to Asieris up to $250m milestones + royalties 2019-07-01
Oncopeptides–SEVERAL: investment, 201906 directed share issue SEK727m ($78m) of 5.015m new shares at SEK145/share 2019-06-27
Sanifit–Lundbeck: investment, 201906 financing round Series D totalling €55.2m incl existing + co-investor Lundbeckfonden Ventures 2019-06-26
UmanDiagnostics–Quanterix: investment, 201906–201907 acquisition $16m in cash + $6.5m in common stock 2019-06-26
Forendo Pharma–Vesalius Biocapital: investment, 201906 existent investment of Vesalius Biocapital III fund 2019-06-25
Sword Health–Vesalius Biocapital: investment, 201906 existent investment of Vesalius Biocapital III fund 2019-06-25
Karolinska Institutet–BGI: DNA sequencing, 201906– collab using DNBSEQ techn for shotgun metagenomics data from microbiome biobank MGI Tech 2019-06-20
Cellink–SEVERAL: investment, 201906 capital raising SEK148.5m with institutional investors 2019-06-18
Spero Therapeutics–Novo Group: investment, 201906– direct offering common stock up to $10m in two tranches of $5m to Novo REPAIR Fund 2019-06-13
JnJ–Genmab: antibody cancer drug, 201906– collab + excl ww license + option agreem for HexaBody-CD38 monoclonal antibody 2019-06-11
Merck (US)–Agilent: molecular companion diagnostics, 201906 collab existent developm of PD-L1 IHC 22CR pharmDx for use with Keytruda 2019-06-11
Saga Diagnostics–Fårö Capital: investment, 201906 financing round totalling SEK40m (€3.7m) incl existing + co-investor Fårö Capital 2019-06-11
Saga Diagnostics–Gunnar Nilsson Cancer Foundation: investment, financing round totalling SEK40m (€3.7m) incl existing + co-investor GNCF 2019-06-11
Saga Diagnostics–Hadean Ventures: investment, 201906 financing round totalling SEK40m (€3.7m) incl new + lead investor Hadean Ventures 2019-06-11
Saga Diagnostics–SEVERAL: investment, 201906 financing round SEK40m (€3.7m) led by new investor Hadean Ventures 2019-06-11
Everest Medicines–Calliditas Therapeutics: Nefecon, 201906– license $15m upfront + $106m milestones + royalties developm + sale for IgAN in China + SG 2019-06-10
Yingsheng Biotechnology–Biotage: clinical mass spectrometry, 201906– collab strategic + OEM sale in China by Shandong Yingsheng Biotechnology 2019-06-04
Oxford BioMedica–Novo Group: investment, 201905–201906 investment £45.3m + optional £8.2m with 6.6m+1.2m new shares at £6.9/share 2019-05-28
Fujifilm–Genovis: enzymes, 201905– collab distribution of SmartEnzymes in Japan + Taiwan + Singapore by Fujifilm Wako Pure Chemical 2019-05-16
Symphogen–Essex Woodlands: investment, 201905– capital increase totalling up to DKK572m incl DKK182m incl existing shareholder Essex Woodlands HC 2019-05-15
Symphogen–Novo Group: investment, 201905– capital increase totalling up to DKK572m incl DKK182m incl existing shareholder Novo Holdings 2019-05-15
Symphogen–PKA: investment, 201905– capital increase totalling up to DKK572m incl DKK182m incl existing shareholder PKA 2019-05-15
Symphogen–SEVERAL: investment, 201905– capital increase up to DKK572m incl DKK182m debt conversion from existing shareholders 2019-05-15
Symphogen–Sunstone Life Science: investment, 201905– capital increase totalling up to DKK572m incl DKK182m incl existing shareholder Sunstone 2019-05-15
Therachon–Novo Group: investment, 201905 existing investor Novo Holdings 2019-05-08
Abide Therapeutics–Lundbeck: investment, 201905 acquisition $250m upfront + $150m milestones of Abide by Lundbeck 2019-05-06
United States (govt)–Cobo Technologies: genome editing, 201904– collab Cobo beomes member of NIST Genome Editing Consortium 2019-04-15
Gilead–Novo Group: drug development, 201904– collab clinical research for NASH combining semaglutide + cilofexor + firsocostat Novo Nordisk 2019-04-12
Probiodrug–SEVERAL: investment, 201904 private placement €8.2m net €7.65m with 4.1m new shares at €2m led by Claus Christiansen et al. 2019-04-09
Gesynta Pharma–SEVERAL: investment, 201904 financing round €6m led by Industrifonden + incl group of private life science investors 2019-04-04
Gesynta Pharma–Sweden (govt): investment, 201904 financing round totalling €6m incl lead investor Industrifonden 2019-04-04
Chr. Hansen–Lonza: microbiomic treatment, 201904– collab establishment 50/50 joint venture for developing + manufacturing microbiome treatments 2019-04-02
next pagenext page 1 2 3 4 5 6 7 8 9 10 11  next pagenext page



Advertisement

Picture [iito] Plain Stupid Simple 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

» top